Clinical Trials Directory

Trials / Completed

CompletedNCT05509296

Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease

A Prospective, Multicenter, Randomized Control, Non-inferiority to Investigate the Effectiveness and Safety of SINOMED CBC for Endovascular Treatment of Stenotic Coronary Artery Disease

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
136 (actual)
Sponsor
Sino Medical Sciences Technology Inc. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to evaluate safety and effectiveness of the SINOMED CBC coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.

Detailed description

The investigation is a prospective, multi-center, randomized control, non-inferiority clinical study. The study will be conducted in up to 8 investigational sites in the China This study will enroll and treat 136 subjects, including in-stent restenosis (ISR). The population for this study is subjects with stenotic coronary artery disease who are suitable candidates for PTCA. After screening for initial inclusion and exclusion criteria, eligible subjects will be asked to participate in the study by signing a consent form. Following consent, subjects will undergo a baseline visit where eligibility criteria will be assessed. Then, subjects will be randomized to either trial balloon (Sino Medical Sciences Technology Inc. ) or to a NSE Coronary Dilatation Catheter (Goodman Co.,Ltd). Angiograms will be performed before and after intervention. Subjects will be followed through hospital discharge.

Conditions

Interventions

TypeNameDescription
DEVICESINOMED CBCThe Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
DEVICENSE Coronary Dilatation CatheterThe Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.

Timeline

Start date
2022-09-20
Primary completion
2022-11-23
Completion
2022-11-23
First posted
2022-08-22
Last updated
2026-03-27
Results posted
2026-03-27

Locations

8 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05509296. Inclusion in this directory is not an endorsement.